Avenue Biosciences, a transatlantic biotechnology company, formulates Advisory Board with distinguished experts in biotechnology and academia: Jens Vogel, Sofia Lund, Gary Zweiger and Ville Paavilainen.

Avenue Biosciences’ protein engineering platform is designed to improve the efficiency and quality of protein production in various biotechnology areas, including mRNA therapies, monoclonal antibodies and synthetic proteins.

The newly assembled Advisory Board strengthens company operations with a wealth of experience from biopharmaceuticals and life sciences.

“A new era of protein-based biologics has begun to unfold thanks to machine learning and AI techniques. Our advisors help us understand the quickly evolving market dynamics and focus our discoveries where they will have the greatest impact”, comments Avenue Biosciences CEO Tero-Pekka Alastalo.

Advisory Board members:

Jens Vogel, PhD

Jens Vogel has a strong track record as senior executive at companies such as Bayer and Boehringer Ingelheim. He has deep expertise in development and manufacturing of diverse biotechnology portfolios (biologics, cell & gene therapy, mRNA), including for customers.‍

Sofia Lund

Entrepreneur, advisor, co-founder. A brand-building expert and executive with two decades of experience, helping life science startups bring their brands to life. Sofia Lund has built successful brands as an executive at companies such as Blueprint Genetics.

Gary Zweiger, PhD

With an experience spanning over three decades, Gary Zweiger has held executive business development positions at Agilent, Affymetrix and ABI. He has a PhD in genetics from Stanford University, and serves as an advisor for private equity and angel investments.

Ville Paavilainen, PhD

Ville Paavilainen is Research Director at the University ofHelsinki with 20+ years of experience in protein science. Paavilainen is deeply involved in small molecule drug discovery and chemical probes projects. He is a co-founder of Avenue Biosciences and a co-inventor of their novel technology.

Further information‍

CEO Tero-Pekka Alastalo, tpa@avenuebiosciences.com

About Avenue Biosciences 

Avenue Biosciences is a biotechnology company dedicated to accelerating the discovery and development of protein biologics, so that no life-saving therapy goes unrealized because of production barriers. Headquartered in San Francisco, USA, and with laboratory operations in Helsinki, Finland, Avenue Biosciences has developed a protein engineering platform that combines organic biologics and machine learning to boost protein production. The proprietary method is based on years of scientific research from the University of Helsinki, Finland. www.avenuebiosciences.com